Advertisement

Topics

Clovis's ovarian cancer drug set for label expansion, shares soar

03:14 EDT 19 Jun 2017 | Reuters

(Reuters) - Positive late-stage data on Clovis Oncology Inc's ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.

Original Article: Clovis's ovarian cancer drug set for label expansion, shares soar

NEXT ARTICLE

More From BioPortfolio on "Clovis's ovarian cancer drug set for label expansion, shares soar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...